Years Ahead in HIV Prevention Research: Time to Market

This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.

The Years Ahead in Biomedical HIV Prevention Research

This graphic shows the updated status of large-scale prevention trials through the end of 2024.

Avac Event

AVAC in Conversation with NIAID’s Jeanne Marrazzo

The new director of National Institute of Allergy and Infectious Diseases (NIAID), Dr. Jeanne Marrazzo joined AVAC Executive Director in conversation.

Vaccine Manufacturing is a Multi-Stage Process Often Requires Extensive Collaboration

This graphic highlights the extensive and complex process of vaccine production, encompassing initial design, drug development, large-scale manufacturing, the creation of administration devices, and finally, distribution.

Excerpted From the Lab to Jab series.

Other mRNA Vaccines in Development

mRNA technology is currently being studied for many different uses. Excerpted From the Lab to Jab series.

How Do mRNA-Based COVID-19 Vaccines Work?

A detailed graphic showing the biological mechanisms by which mRNA vaccines work. Excerpted From the Lab to Jab series.

Getting the COVID-19 Vaccines We Need

As of March 2023, the World Health Organization reported that there are 199 COVID-19 vaccines in pre-clinical development, and 183 in clinical trials. Most are injectable; but 16 candidates are intranasal, 5 are oral, 2 are inhalable, and 1 is an aerosol.

HIV Vaccine Research

HIV vaccine research is a multifaceted endeavor that requires collaboration across many disciplines to develop a vaccine that protects people from HIV infection. The graphic outlines the different areas of research that are being pursued, including vaccine platforms, immune system research, clinical research capacity, and community engagement.

Excerpted From Lab to Jab.

Vaccine Research and Development: Key Lessons and Ways Forward

From Lab to Jab

This issue brief on the vaccine research and development (R&D) process is one of a series of four briefs, which provide a roadmap for advocacy to advance the development of essential vaccines for HIV, COVID-19, tuberculosis, and other global public health threats, and approaches to ensure equitable access to these life-saving vaccines. Additional topics cover the role of mRNA technology, the need for local vaccine production, and issues around global access.

Vaccine Access: What’s Working and What’s Next

From Lab to Jab

This issue brief covers the web of issues that influence access to vaccines. It is one of a series of four issue briefs, which provide a roadmap for advocacy to advance the development of essential vaccines for HIV, COVID-19, tuberculosis, and other global public health threats, and approaches to ensure equitable access to these life-saving vaccines. Additional topics cover the research and development (R&D) process, the role of mRNA technology; and the need for local vaccine production.